Plain-English translation of NCT06468267 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a stem cell transplant procedure combined with four chemotherapy drugs—, busulfan, fludarabine, and cytarabine—for people with a type of lymphoma called peripheral T-cell lymphoma that has either come back after treatment or never responded to standard chemotherapy. The chemotherapy drugs are given at reduced doses to prepare your body for the transplant, which uses healthy blood-forming stem cells from a matched donor. The goal is to see whether this combination can help control the cancer and improve survival.
Many patients with peripheral T-cell lymphoma either have their cancer return or find that standard treatments don't work well enough. Using a lower-dose chemotherapy regimen may reduce serious side effects while still allowing the transplanted donor cells to fight the cancer effectively.
You will be admitted to the hospital for about 2–3 weeks to receive the chemotherapy regimen and the stem cell transplant. Starting 7 days before the transplant, you will receive the four chemotherapy drugs on a carefully timed schedule. On day 0, you will receive the donated stem cells through an infusion. After transplant, you will have frequent bone marrow biopsies and blood tests during the first year (on days 14 and 28, then every 30 days for the first year, then every 60 days in the second year), plus imaging scans every 6 months. You will be followed closely for at least 2 years to see how well the treatment works and to monitor for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China